dipyridamole

CLINICAL USE

Antiplatelet agent

DOSE IN NORMAL RENAL FUNCTION

100–200 mg 3 times dailyModified release: 200 mg twice daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :504.6

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97–99

%Excreted unchanged in urine &nbsp &nbsp : 1–5

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.33–3.53

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :9–12/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Not dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAnti-arrhythmics: effects of adenosine enhanced and extendedAnticoagulants: anticoagulant effect of coumarins, phenindione and heparin enhanced

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–.

Tags: post-by-auto-php